Business
Biomira to web cast 2006 Annual General Meeting
Biomira to web cast 2006 Annual General Meeting.
About this update from Skrr Exploration, Inc.
[{"type":"text","content":"\n\n\n\n\nEDMONTON, May 16 /CNW/ - Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) today\nannounced that it will web cast its Annual General meeting tomorrow morning at\n11:00 a.m. EDT.\nDr. Alex McPherson, Biomira's President and CEO will review:\n\n - Last year's highlights, including, the progress and latest update\n on STIMUVAX(R), the Company's lead product candidate for non small\n cell lung cancer and its amended arrangements with collaboration\n partner, Merck KGaA of Darmstadt, Germany\n - Plans for broadening Biomira's pipeline and leveraging its\n Synthetic Biologics Business Unit to explore out-licensing\n opportunities\n - Next steps on its follow-on vaccine, BGLP40\n - Business development opportunities\n\nThe meeting will take place at the Delta Edmonton South Hotel, Edmonton,\nAlberta, Canada.\n\nWeb Cast Details\nTo listen to the live web cast of the President's address please log on\nat approximately 11:10 a.m. EDT to:\nhttp://www.newswire.ca/en/webcast/viewEvent.cgi?eventID(equal sign)1401400.\nYou will be held in queue until Dr. McPherson's presentation commences,\nfollowing the business portion of the meeting. A very limited number of\ntelephone lines are available for those without internet access. Participant\nnumbers are 1-800-814-4862 or 1-416-644-3430. Conference replay is available\nfor 48 hours following the meeting and will be available at approximately\n2:30 p.m. EDT. The dial in numbers are 1-416-640-1917 or 1-877-289-8525. The\npasscode is 21182498 followed by the number sign.\n\nBiomira\nBiomira is a biotechnology company specializing in the development of\ninnovative therapeutic approaches to cancer management. Biomira's commitment\nto the treatment of cancer currently focuses on the development of synthetic\nvaccines and novel strategies for cancer immunotherapy. We are The Cancer\nVaccine People(TM).\n\nExcept for historical information contained herein, this release contains\nforward-looking statements that are subject to risks and uncertainties that\nmay cause actual results to differ materially from the results discussed in\nthe forward-looking statements, particularly those risks and uncertainties\nsurrounding Stimuvax(R) to treat men and women with NSCLC, which may include\nrisks and uncertainties inherent in the process of discovering, developing and\ncommercializing drugs that are safe and effecti...